# NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

> **NCT04698681** · — · TERMINATED · sponsor: **Calithera Biosciences, Inc** · enrollment: 20 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Non-squamous Non-small-cell Lung Cancer
- Non-Squamous Non-Small Cell Neoplasm of Lung
- KEAP1 Gene Mutation
- NRF2 Mutation
- NFE2L2 Gene Mutation

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04698681
- **Lead sponsor:** Calithera Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-19
- **Primary completion:** 2021-11-05
- **Final completion:** 2022-02-09
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Lack of Clinical Benefit
- **Last updated:** 2023-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04698681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04698681, "NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04698681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*